Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan/Temozolomide with Temsirolimus or Dinutuximab in Neuroblastoma (ANBL1221)
NCT01767194Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2013
- Primary completion
- Jun 2018
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of dinutuximab, temsirolimus in neuroblastoma, ganglioneuroblastoma (GNB), sponsored by National Cancer Institute. Started Feb 2013; status: completed.
02
Drugs
dinutuximabtemsirolimus
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on NCT01767194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01767194.